INTRODUCTION

Mutations in the isocitrate dehydrogenase (IDH)
IDH1 and IDH2 genes revealed a novel mechanism of cancer formation and uncovered new therapeutic opportunities. These enzymes normally catalyze a Krebs cycle-like reaction, namely the conversion of isocitrate to alpha-ketoglutarate (aKG) coupled with NADPH (nicotinamide adenine dinucleotide phosphate) production, which is essential for oxidative stress response and several metabolic pathways. Mutated IDH enzymes produce the D stereoisomer of 2-hydroxyglutarate (2-HG) from aKG. 1 As a result, tumor cells accumulate massive amounts of 2-HG, which can interfere with aKG-dependent dioxygenases, including histone and DNA demethylases, such as TET2. [2] [3] [4] In vitro data and a mouse model concurrently indicated that in hematopoietic cells, IDH1/2 mutations lead to major alterations of epigenetic marks throughout the genome.
5,6
IDH1/2 mutations are found in 15% to 20% of patients with AML (Յ 30% in patients with normal karyotype).
7-9 IDH1/2 mutations are thought to be an early oncogenic event in AML. 10 The clinical impact of these mutations may depend on the specific mutation (eg, IDH2 R140, R132, or R172) and on the presence of associated mutations, such as FLT3 internal tandem duplication (FLT3-ITD) or NPM1.
8,11-13 Detection of IDH1/2 mutations and quantitation of 2-HG in blood may therefore provide markers proximal to the mechanism of disease, which could help to optimize treatment and follow-up of this subset of AML. Several studies have shown increased levels of total serum 2-HG in small cohorts of patients with AML with IDH1/2 mutations, 14-19 but none have investigated long-term follow-up or measured the specific product of the mutated enzymes (ie, D stereoisomer v unrelated (L) stereoisomer of 2-HG).
We measured levels of total 2-HG (ie, sum of D and L stereoisomers) and the ratio between the two stereoisomers (D to L) in serum or plasma from a cohort of 82 patients with de novo AML and 68 patients without AML. We tested the diagnostic value of these two markers to identify IDH1/2 mutations as well as their prognostic significance and whehter they correlated with known minimal residual disease (MRD) markers.
PATIENTS AND METHODS
Study Population and Data Collection
Serum or plasma samples from 150 patients with (n ϭ 82) and without AML (n ϭ 68) were analyzed for 2-HG levels (Fig 1) . Among those with AML, 53 had IDH1/2 mutations, and 29 consecutive patients were IDH1/2 wild type. Samples from patients with AML were collected at diagnosis between 2005 and 2012 through a collaborative network of French centers (Creteil, Dijon, Lille, Paris Saint Louis, and Villejuif) for the Acute Leukemia French Association (ALFA) group. All patients were investigated for IDH1, IDH2, AML1/RUNX1, CEBPA, FLT3, and NPM1 mutations as described.
11 They all had intermediate-risk cytogenetics (except one because of karyotype failure), but the cohort was enriched in IDH1/2-mutated patients. Fifty-two patients were included in the ALFA-0701 20 and -0702 trials (ClinicalTrials.gov Identifier: NCT00932412). Thirty patients received intensive treatment according to ALFA protocols, combining anthracyclines and cytarabine. 21, 22 All patients signed written informed consent. For follow-up studies, we analyzed 171 serum or plasma samples from 36 patients with AML with IDH1/2 mutations (at diagnosis, in complete remission [CR], or with refractory disease) after consolidation courses, during follow-up, and at relapse. Serums were analyzed along with molecular markers of MRD (NPM1 mutation, WT1 expression) as reported.
23,24 MRD levels were assessed using cDNA-based real-time quantitative polymerase chain reaction (PCR) and reported as the ratio of NPM1 mutation or WT1 transcript to 100 ABL transcript. WT1 overexpression at diagnosis was defined as a ratio of WT1 to ABL transcript Ͼ 25% in bone marrow (BM) or 5% in peripheral blood (PB) samples. Samples were collected at diagnosis, after induction, after consolidation course, during follow-up, and at relapse.
2-HG measurements in plasma samples of the 68 patients without AML were analyzed per routine diagnostic procedure at the Necker Hospital (Paris, France) for the workup of 50 consecutive patients with putative metabolic disorders or during the follow-up of known inherited metabolic diseases (n ϭ 18). Basic characteristics of patients without AML are listed in Appendix Table  A1 (online only).
Quantification of IDH1/2 Mutation Burden
Genomic DNA was extracted from BM or PB samples using conventional procedures. IDH1-(codon R132) and IDH2-targeted (codons R140 and R172) regions were amplified by PCR with primers (available on request) containing Ion Torrent (Life Technologies, Carlsbad, CA) adapters and unique barcodes to generate libraries. Pooled amplicon libraries were clonally amplified on Ion Spheres using the Ion Xpress Template 200 Kit (Life Technologies) and then bidirectionally sequenced on Ion Torrent Sequencer. The relative IDH1/2 mutational burden was determined as number of normal to mutant reads.
2-HG Analysis
Plasma or serum samples (dry lithium heparin) from the reference population (n ϭ 68) and patients with AML (n ϭ 82) were analyzed in the Reference Center for Metabolic Disorders at Necker Hospital. To each 100-L sample we added 0.5 nmoles of 1,2,3,4-13C4 -labeled 2-HG, prepared by reduction of labeled aKG (Eurisotop, Saint-Aubin, France) as the internal standard. Analysis was performed in selected-reaction monitoring mode by gas chromatography-tandem mass spectrometry on a GC 450/300-MS triple quadrupole (Varian, Brüker Daltonics, Fremont, CA). Sample processing was performed as reported. 25 Calibration curves were linear between Ͻ 20 pmoles and Ͼ 400 nmoles. The limit of quantification was 50 pmoles, with a coefficient of variation Ͻ 10%. The laboratory participates in the International External Quality Assurance Programme for Quantitative Organic Acids (http://cms.erndimqa.nl/).
Statistical Analysis
Analyses were performed using the SAS software (version 9.2; SAS Institute, Cary, NC) and R language-based software (version 2.14; (http://www. r-project.org). Area under the receiver operating characteristic curve (ROC AUC) was estimated using the pROC package (R software; 95% CIs estimated using de Long method). Correlations between 2-HG and hematologic parameters or molecular markers of follow-up were estimated with Spearman rankorder correlation coefficient. Progression-free survival (PFS) was estimated for patients in CR from the date of diagnosis to date of progression. Patients who died without progression were considered censored at the date of death. The Kaplan-Meier method was used to perform univariate survival analyses; the log-rank test was used to test statistical significance. Cox regression analysis was performed to identify independent prognostic parameters. All P values were two tailed, and the level of significance was P Ͻ .05.
RESULTS
IDH1/2 Gene Mutation Profile in the Study Population
Initial characteristics of 82 patients with de novo AML are summarized in Table 1 , with details listed in Appendix Table A2 (online  only) . Fifty-three of these patients (64%) were had IDH1/2 mutations and were compared with 29 consecutive patients with de novo AML without IDH1/2 mutations. IDH1/2 mutations were associated with NPM1 mutations (P Ͻ .001) but not with FLT3 mutations (neither ITD nor tyrosine kinase domain [TKD] ) and had higher percentage of bone marrow blasts (P ϭ .04) compared with IDH1/2 wild type ( Table 1) .
2-HG Plasma Level and D to L Stereoisomer Ratio in Patients Without AML
We measured plasma 2-HG levels in a reference population that included 50 consecutive adult patients without metabolic disorders (nonmetabolic reference population) and 18 pediatric or adult patients with known inherited metabolic disease but without mutations in IDH1/2 or D-2 or L-2 hydroxyglutarate dehydrogenase genes (metabolic reference population; Appendix Table A1 , online only). The latter were meant to provide relevant information for metabolic disturbances that may affect 2-HG levels by acting upstream or downstream of the IDH1/2 enzymes. Because IDH1/2 mutations produce the D stereoisomer and not the L stereoisomer, we calculated the ratio between D and L to determine which stereoisomer was responsible for increased total 2-HG. Indeed, increased levels of the L stereoisomer may confound the analysis of total 2-HG, producing false positives. Median total 2-HG (total 2-HG) levels were 1.1 mol/L (range, 0.7 to 2.2 mol/L) for the 50 nonmetabolic patients and 1.5 mol/L (range, 0.6 to 30.4 mol/L) for the 18 metabolic patients (Fig 2A) . Metabolic patients had a higher median D to L ratio (1.3; range, 0.6 to 6.8) than nonmetabolic patients (0.9; range, 0.2 to 3.9; Wilcoxon rank sum test P ϭ .003; Fig 2B) but had similar total 2-HG levels (median, 1.4; range, 0.6 to 30.4 v median, 1.1; range, 0.7 to 2.2 mol/L, respectively; Wilcoxon rank sum test P ϭ .18). One patient with a metabolic disorder had a 2-HG level as high as 30 mol/L but a normal D to L ratio. Overall, these data suggest that some metabolic disturbances may significantly alter 2-HG levels, thereby confounding analysis of patients with AML.
Prediction of IDH1/2 Mutational Status of Patients With AML at Diagnosis
Patients with AML without IDH1/2 mutations (n ϭ 29) had median total 2-HG levels (1.2; range, 0.8 to 3.6 mol/L) similar to those of nonmetabolic patients (1.1; range, 0.7 to 2.2 mol/L) and metabolic patients (1.5; range, 0.6 to 30.4 mol/L; Wilcoxon rank sum test P ϭ .08, Fig 2A) . In contrast, patients with AML with IDH1/2 mutations had a markedly higher median level (21.2; range, 2.4 to 305.9 mol/L; P Ͻ .001). Median D to L ratio was 0.9 (range, 0.2 to 1.9) for IDH1/2 wild-type patients with AML and 22.9 (range, 3.1 to 51.2) for patients with AML with IDH1/2 mutations (Fig 2B) . Total 2-HG level and D to L ratio that ensured maximum specificity at 100% sensitivity to detect IDH1/2 mutations were approximately 2 mol/L and 2.5, respectively. At these optimal screening cutoffs, among patients with AML, D to L ratio showed better specificity (100%) than total 2-HG (79%; McNemar test P ϭ .031). Thus, only the D to L ratio led to complete separation between patients with AML with or without IDH1/2 mutations. Nevertheless, this picture may be overoptimistic, because the inclusion of patients without AML reduced specificity of the D to L ratio to 96% (misclassifications included ratios between 3.9 and 6.8 from reference population; Fig 2B) .
High values for either total 2-HG or D to L ratio were strongly predictive of the presence of IDH1/2 mutations. Both had ROC AUCs Ͼ 99%, with 95% CI of 98% to 100% (Fig 2C; Appendix Fig  A1A, online only) . Interestingly, in two patients with AML, IDH1/2 mutations that had not been detected with the classical Sanger method were revealed by high levels of 2-HG. Deep sequencing identified IDH1 R132C and IDH2 R140Q mutations (in patients No. 6 and 37, respectively; Appendix Table A2 , online only) at allelic burdens of 10% and 20%, respectively.
Parameters Associated With High 2-HG Level at Diagnosis
We found a strong positive correlation between allelic burden and D to L ratio in patients with IDH1/2 mutations (P Ͻ .001; r 2 ϭ 0.489; Appendix Figure A2A , online only). D to L ratio also showed positive correlation with WBC counts (P Ͻ .001; r 2 ϭ 0.301; Appendix Fig A2B, online only) . Neither FLT3-ITD or -TKD mutations nor NPM1 mutations were associated with D to L ratio or total 2-HG (P ϭ .89 and P ϭ .1, respectively).
Presence of the IDH2 R172K mutation was associated with increased total 2-HG and D to L ratio compared with IDH2 R140 and IDH1 R132 mutations (Kruskal Wallis test P ϭ .02 and P ϭ .04, respectively; Fig 2D; Appendix Fig A1B, online only) Table A2 , online only) showed normal levels of 2-HG.
2-HG Level Reflects Clinical Status and Correlates With MRD Markers
The serial collection of total 171 serum samples from 36 patients with IDH1 or IDH2 mutations included time points at diagnosis, after induction treatment, during follow-up, and at relapse. Median 2-HG level and D to L ratio in samples at CR were significantly lower (1.3 mol/L and 1.4, respectively) than those from patients who did not achieve CR after one induction course (6.2 mol/L and 8. Finally, the relation between 2-HG level and MRD was assessed by comparing 2-HG levels with mutated NPM1 burden (n ϭ 17 patients) or WT1 expression levels (n ϭ 19 patients; Fig 4; Appendix  Fig A3B, online only) at diagnosis, at CR, and during follow-up (persistent CR and relapsing patients). A positive correlation was observed between 2-HG level (either total 2-HG or D to L ratio) and WT1 expression in blood (n ϭ 48 paired samples), WT1 expression in BM (n ϭ 41), NPM1 in blood (n ϭ 37), and NPM1 in bone marrow (n ϭ 39; all correlations significant at P Ͻ .001; r 2 Ͼ 0.3; Fig 4; Appendix Fig  A3B, online only) . Thus, both total 2-HG and D to L ratio are good candidate markers of MRD.
Prognostic Impact of Postinduction 2-HG Levels in Patients With IDH1/2 Mutations
Median follow-up of the 53 patients with IDH1/2 mutations was 2.9 years (95% CI, 2 months to 6.9 years). Two died during induction treatment, and eight were refractory (five of 20 with IDH1 R132 and three of nine with IDH2 R172 mutations). Forty-three of these patients (13 of 20 with IDH1 R132, 24 of 24 with IDH2 R140, and six of nine with IDH2 R172 mutations) achieved CR (81%). After CR achievement, 22 relapsed, and 14 died.
In these 53 patients with IDH1/2 mutations, univariate prognostic analyses of IDH1 R132, IDH2 R140Q, IDH2 R172K, FLT3-ITD, FLT3-TKD, and NPM1 mutations and initial levels of total 2-HG (Ͼ or Ͻ median level; median, 21.2; range, 2.4 to 305.9 mol/L) revealed that at diagnosis, only the presence of NPM1 mutation had a significant impact on outcome, because it predicted better overall survival (OS; P ϭ .005) although not PFS (log-rank test P ϭ .1; Appendix Fig  A4, online only) . The impact of NPM1 on OS remained significant after adjustment for age (age as continuous covariable: hazard ratio [HR], 0.26; 95% CI, 0.08 to 0.79; P ϭ .02; Appendix Table A3 , online only).
Postinduction serum samples were available for 31 of the 43 patients who achieved CR. Median total 2-HG and D to L ratio 
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www.jco.org were 1.7 mol/L (range, 0.7 to 25.9 mol/L) and 1.88 (range, 0.7 to 23.2), respectively. In these 31 patients with IDH1/2 mutations in CR, 15 relapsed, and four died (all after relapse). Univariate prognostic analyses of IDH1 R132, IDH2 R140Q, FLT3-ITD, and NPM1 mutations and total 2-HG at CR revealed that only 2-HG level at CR had a significant impact on outcome (Table 2 ). This impact on PFS remained significant after adjustment for age (age as continuous covariable: HR, 4.37; 95% CI, 1.14 to 16.8; P ϭ .032; Table 2 ). Patients with total 2-HG levels at CR Ͻ diagnostic cutoff (ie, Ͻ 2 mol/L) had significantly better PFS (P ϭ .005) and OS (P ϭ .008; Fig 5) . The diagnostic cutoff for the D to L ratio (2.5) at CR was not significantly prognostic of PFS (P ϭ .17) or OS (P ϭ .13). 
DISCUSSION
This study suggests that 2-HG released by blast cells in the serum is a biomarker of IDH1/2 mutations, presumably reflecting the neomorphic enzymatic activity of the mutants. Total 2-HG level correlated with allelic burden and tumor mass. Consistently, 2-HG levels were significantly associated with clinical status (ie, CR v absence of CR) and correlated with available markers of MRD (ie, NPM1 mutation or WT1 overexpression). This suggests that serum 2-HG can serve as a marker of MRD. Patients who achieved CR with total 2-HG levels Ͼ diagnostic cutoff (ie, 2 mol/L) had decreased PFS and OS. Because 2-HG levels were elevated in the presence of low mutation burden, the biochemical assay for serum 2-HG may be an efficient, fast, and cost-effective complement to molecular analysis. In addition, serum 2-HG may be of particular interest in follow-up when standard molecular markers are not available (ie, presence of IDH1/2 mutations but absence of NPM1 mutations and/or normal WT1 expression levels). This remains to be confirmed in future prospective studies. 2-HG levels may be informative beyond de novo AML (eg, IDH1/2 mutations frequently occur in myelodysplastic syndromes and myeloproliferative diseases when they undergo transformation 28, 29 ). As a national reference center for metabolic disorders, we extended the analysis to a reference population of patients with suspected or known metabolic conditions that could affect 2-HG production independent of IDH1/2 mutations. This provided a framework to better appreciate the strength of the association between 2-HG and different clinical situations. We determined the cutoff of serum total 2-HG level (ie, 2 mol/L) that detected all patients with AML with IDH1/2 mutations while excluding the greatest fraction of patients and controls with normal IDH (thus achieving 89% specificity at 100% sensitivity). In addition, we reasoned that because only the D form is produced by IDH1/2-mutant enzymes, 1,27,30 specificity could further increase if we were to measure the level of the IDHspecific D form or ratio between D and the alternative L form rather than total 2-HG. Indeed, when we considered the entire sample of patients with AML and controls without AML, the D to L ratio (with cutoff at 2.5) provided better specificity than total 2-HG to predict IDH1/2 mutations (96% v 89% at 100% sensitivity). D to L ratio actually led to complete separation between the two groups of patients with AML (IDH1/2 mutations v IDH1/2 wild type). The diagnostic performance of serum D stereoisomer alone was identical to that of the D to L ratio (data not shown). However, the D to L ratio has the additional advantage of being technically more reliable than measuring 2-HG concentrations (whether total or D stereoisomer), because its quantification does not require the addition of an internal standard. Therefore, we focused on the D to L ratio rather than the D stereoisomer as a complementary method to the more standard assay for total 2-HG.
Presence of IDH1/2 mutations is relevant for prognosis and treatment of a subset of patients with AML. 13 Recent results further indicate that a small-molecule selectively inhibits 2-HG production by IDH1 R132 mutation.
31 Therefore, we argue that total 2-HG can serve as a surrogate marker of treatment efficacy. In addition, our finding that total 2-HG level at CR was significantly predictive of outcome could be of particular interest for patients with a so-called favorable genotype (ie, NPM1 mutations associated with IDH1 or IDH2 in absence of FLT3-ITD). 13 In these patients, elevated levels of total 2-HG after induction therapy could modify therapeutic options, notably making a stronger case for allogeneic stem-cell transplantation.
Finally, our data raise the possibility that additional metabolic markers could be useful in follow-up studies. Indeed, outcome was significantly predicted by total 2-HG, but not or only weakly by D to L ratio. We infer that other putative sources of metabolic dysfunction that involve the L form of 2-HG might affect outcome.
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‫ء‬
Including succinic semialdehyde dehydrogenase deficiency, glutaric aciduria type 1, propionic and isovaleric aciduria, and alkaptonuria. †Including ornithine transcarbamoylase deficiency, arginase deficiency, lysinuric protein intolerance, cystathione beta-synthetase deficiency, and phenylketonuria. ‡Including pyruvate dehydrogenase deficiency and respiratory chain complex IV and I deficiency. §Including cognitive impairment, pyramidal and or extrapyramidal symptoms, epilepsy, and hypotonia. ʈIncluding lethargy, vomiting, malnutrition, hypoglycemia, metabolic acidosis, ketoacidosis, hyperammonemia, microcephaly, and disorders of neural development. 
